Rchr
J-GLOBAL ID:201801009871345762   Update date: Sep. 01, 2020

Miyahara Yoshihiro

ミヤハラ ヨシヒロ | Miyahara Yoshihiro
Affiliation and department:
Research field  (2): Tumor diagnostics and therapeutics ,  Immunology
Research keywords  (4): 遺伝子改変T細胞療法 ,  neo-antigen ,  Immune response ,  Tumor Immunology
Research theme for competitive and other funds  (5):
  • 2018 - 2021 Development of an innovative CAR-T therapy using T cell receptor-like antibody and GITR intracellular domain for solid tumors
  • 2017 - 2020 難治性肉腫に対する ワクチン併用TCR遺伝子改変T細胞輸注療法の多施設共同医師主導治験
  • 2016 - 2019 新規免疫応答測定法を利用した複合療法開発への基盤研究
  • 2017 - 2018 成人T細胞白血病/リンパ腫に対するT細胞受容体遺伝子導入リンパ球輸注療法の開発
  • 2011 - 2014 末梢におけるFOXP3陽性制御性T細胞への分化メカニズム解析とがん治療への応用
Papers (31):
  • Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. The Journal of clinical investigation. 2019
  • Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H, Kageyama S. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget. 2018. 9. 89. 35997-36011
  • Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood. 2018. 132. 11. 1134-1145
  • Takehiro Abiko, Takahiro Tsuchikawa, Kengo Miyauchi, Masataka Wada, Noriaki Kyogoku, Toshiaki Shichinohe, Yoshihiro Miyahara, Shinichi Kageyama, Hiroaki Ikeda, Hiroshi Shiku, et al. Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncology Letters. 2018. 15. 3. 3703-3711
  • Masataka Wada, Takahiro Tsuchikawa, Noriaki Kyogoku, Takehiro Abiko, Kengo Miyauchi, Shintaro Takeuchi, Toshihiko Kuwatani, Toshiaki Shichinohe, Yoshihiro Miyahara, Shinichi Kageyama, et al. Clinical implications of CD4+CD25+Foxp3+regulatory t cell frequencies after chp-mage-a4 cancer vaccination. Anticancer Research. 2018. 38. 3. 1435-1444
more...
MISC (8):
Patents (9):
Lectures and oral presentations  (67):
  • 腫瘍におけるNY-ESO-1発現と抗体反応はMAGE-A4ワクチン療法を受ける食道・頭頸部癌患者の予後不良を示す(NY-ESO-1 expression and antibody related to poor outcome in MAGE-A4-vaccinated esophageal and head/neck cancer patients)
    (日本癌学会総会 2018)
  • ひとつのマウス自然発生肉腫に由来する免疫原性、血管新生能の異なる3クローンの樹立(Three clones derived from a spontaneous mouse sarcoma representing distinct immunogenicity and vasculogenic activities)
    (日本癌学会総会 2018)
  • ヒト大腸がん組織に浸潤する腫瘍反応性CD8陽性T細胞の表現型および遺伝子解析(Phenotypic and genetic characteristics of tumor-reactive CD8+ T cells existing in human colorectal tumor tissue)
    (日本癌学会総会 2018)
  • 有望な遺伝子改変γδ T細胞を用いたがん免疫療法(Promising use of gene-modified γδ T cells for Cancer Immunotherapy)
    (日本癌学会総会 2018)
  • Cytokine Release Syndrome and Tumor Responses in a First-in-Man Trial of a Novel Affinity-Enhanced TCR-Gene Transduced T Cell Transfer Targeting NY-ESO-1 Antigen
    (American Society of Hematology (ASH) 2017)
more...
Professional career (1):
  • 医学博士 (三重大学)
Association Membership(s) (3):
Japanese Association of Cancer Immunology ,  THE JAPANESE SOCIETY FOR IMMUNOLOGY ,  THE JAPANESE CANCER ASSOCIATION
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page